- Home
- ARQT
as 11-05-2025 4:00pm EST
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | WESTLAKE VILLAGE |
| Market Cap: | 2.1B | IPO Year: | 2020 |
| Target Price: | $22.17 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.45 - $27.08 | Next Earning Date: | 10-28-2025 |
| Revenue: | $317,929,000 | Revenue Growth: | 129.21% |
| Revenue Growth (this year): | 85.27% | Revenue Growth (next year): | 30.70% |
Stock Insider Trading Activity of Arcutis Biotherapeutics Inc. (ARQT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Burnett Patrick | ARQT | See Remarks | Nov 5 '25 | Sell | $23.72 | 7,728 | $183,286.52 | 98,325 | |
| Matsuda Masaru | ARQT | See Remarks | Nov 3 '25 | Sell | $25.06 | 14,416 | $356,311.53 | 154,026 | |
| Burnett Patrick | ARQT | See Remarks | Nov 3 '25 | Sell | $25.06 | 5,244 | $129,612.45 | 98,325 | |
| Watanabe Todd Franklin | ARQT | See Remarks | Nov 3 '25 | Sell | $25.06 | 23,094 | $570,798.34 | 794,962 | |
| Welgus Howard G. | ARQT | Director | Nov 3 '25 | Sell | $25.27 | 20,000 | $505,338.00 | 89,744 | |
| Vairavan Latha | ARQT | SVP Chief Financial Officer | Nov 3 '25 | Sell | $24.72 | 176 | $4,350.46 | 64,927 | |
| Watanabe Todd Franklin | ARQT | See Remarks | Oct 28 '25 | Sell | $25.03 | 40,000 | $1,001,032.00 | 794,962 | |
| Watanabe Todd Franklin | ARQT | See Remarks | Oct 2 '25 | Sell | $20.04 | 20,739 | $415,574.30 | 794,962 | |
| Edwards Larry Todd | ARQT | See Remarks | Oct 2 '25 | Sell | $20.38 | 4,504 | $90,263.31 | 179,324 | |
| Watanabe Todd Franklin | ARQT | See Remarks | Oct 1 '25 | Sell | $19.46 | 24,261 | $469,074.38 | 794,962 |
Latest Arcutis Biotherapeutics Inc. News
ARQT Breaking Stock News: Dive into ARQT Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Arcutis Biotherapeutics Says Skin Disease Treatment for Children Ages 2 to 5 Gets US FDA Approval
GlobeNewswire
a month ago
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
Zacks
a month ago
Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last?
Simply Wall St.
a month ago
Arcutis Biotherapeutics (ARQT): Evaluating Valuation as Upward Earnings Revisions Fuel Renewed Investor Interest
MT Newswires
a month ago
Arcutis Biotherapeutics Insider Sold Shares Worth $884,649, According to a Recent SEC Filing
GlobeNewswire
a month ago
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
a month ago
Arcutis Biotherapeutics, Inc. (ARQT) Hit a 52 Week High, Can the Run Continue?
GlobeNewswire
a month ago
Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025
Compare ARQT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARQT Arcutis Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.